Green Pharma

Green pharma is largely based on the study and recommendations put forward in a 1998 publication by Paul T. Anastas and John C. Warner, entitled Green Chemistry: Theory and Practice. The central tenet developed for this new approach to chemistry can be very easily applied to pharmaceutical development and manufacture. Broadly, green chemistry is;

…the utilization of a set of principles that reduces or eliminates the use or generation of hazardous substances in the design, manufacture and application of chemical products.

In more detail, Anastas and Warner propose twelve principles which should be central to the planning and processes of pharmaceutical development and manufacture. They are:

  • Prevention; design chemicals and processes that prevent or minimise waste
  • Atom Economy; design efficient processes that essentially involve as few atoms as possible
  • Less hazardous chemical synthesis; eliminate or minimise toxic substances used in processes
  • Designing safer chemicals; eliminate or minimise the presence of toxic substances in the chemical being created or manufactured
  • Safer solvents and auxiliaries; avoid using solvents, separation agents where possible. When they must be used, use the least toxic and most innocuous chemical.
  • Design for energy efficiency; design processes and use technology with optimal energy efficiency and minimal waste.
  • Use of renewable feedstocks; use renewable substances, stocks and ingredients over those which are depleting (ie, fossil fuels)
  • Reduce derivatives; avoid chemical derivatives which generate waste
  • Catalysis; use catalyst processes which are more efficient, use less material and produce a reaction repeatedly.
  • Design for degradation; design chemicals which break down into innocuous substances and do not accumulate in the environment.
  • Real-time analysis for pollution prevention; monitor and control all processes to minimise or eliminate byproducts
  • Inherently safer chemistry for accident prevention; design chemicals that are ‘safe’ in all forms (solid, liquid, gas) and minimise potential for accidents, such as explosion, fires and environmental damage.

    While not an established group or doctrine, the principles of green chemistry and its influence on modern pharmaceutical development and manufacturing have evolved rapidly and organically to give the industry several shining examples of drug companies, products and processes that are ‘benign by design’.

    Related posts on the Clinuvel blog

    Clinuvel Blog Posts

    Today, February 28, marks Rare Disease Day: an annual event to help highlight the effects of rare diseases on individuals, families and the...

    Read More

    We've just released the first results from our vitiligo program which you can view online here. Following their release, we expect a number...

    Read More

    I find vitiligo to be a fascinating, yet devastating disorder: almost overnight, patients see their skin colour erode and their identity...

    Read More

    Clinuvel Webcasts

    Taking on Vitiligo, a depigmentation disorder of the skin. In 2010, Clinuvel ventured into an area of dermatology where no other pharmaceut...

    Watch now

    Taking on Vitiligo, a depigmentation disorder of the skin. In 2010, Clinuvel ventured into an area of dermatology where no other pharmaceut...

    Watch now

    Taking on Vitiligo, a depigmentation disorder of the skin. In 2010, Clinuvel ventured into an area of dermatology where no other pharmaceut...

    Watch now

    Clinuvel Spotlight

    The technology behind Clinuvel’s lead drug, SCENESSE® (afamelanotide), has been in research and development since the 1980s when a small team of scientists set out to investigate methods of preventing skin cancer in humans. Clinuvel licensed this technology and has spent over A$20million optimising the chemistry of afamelanotide (the active ingredient in SCENESSE®) an...

    Read more